Literature DB >> 17174914

Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells.

Kian-Huat Lim1, Kevin O'Hayer, Stacey J Adam, S Disean Kendall, Paul M Campbell, Channing J Der, Christopher M Counter.   

Abstract

BACKGROUND: The Ral guanine nucleotide-exchange factors (RalGEFs) serve as key effectors for Ras oncogene transformation of immortalized human cells. RalGEFs are activators of the highly related RalA and RalB small GTPases, although only the former has been found to promote Ras-mediated growth transformation of human cells. In the present study, we determined whether RalA and RalB also had divergent roles in promoting the aberrant growth of pancreatic cancers, which are characterized by the highest occurrence of Ras mutations.
RESULTS: We now show that inhibition of RalA but not RalB expression universally reduced the transformed and tumorigenic growth in a panel of ten genetically diverse human pancreatic cancer cell lines. Despite the apparent unimportant role of RalB in tumorigenic growth, it was nevertheless critical for invasion in seven of nine pancreatic cancer cell lines and for metastasis as assessed by tail-vein injection of three different tumorigenic cell lines tested. Moreover, both RalA and RalB were more commonly activated in pancreatic tumor tissue than other Ras effector pathways.
CONCLUSIONS: RalA function is critical to tumor initiation, whereas RalB function is more important for tumor metastasis in the tested cell lines and thus argues for critical, but distinct, roles of Ral proteins during the dynamic progression of Ras-driven pancreatic cancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17174914     DOI: 10.1016/j.cub.2006.10.023

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  131 in total

1.  Cell motility: The necessity of Rac1 GDP/GTP flux.

Authors:  Maria Carla Parrini; Jacques Camonis
Journal:  Commun Integr Biol       Date:  2011-11-01

2.  RalA and RalB proteins are ubiquitinated GTPases, and ubiquitinated RalA increases lipid raft exposure at the plasma membrane.

Authors:  Vincent Neyraud; Vasily N Aushev; Anastassia Hatzoglou; Brigitte Meunier; Ilaria Cascone; Jacques Camonis
Journal:  J Biol Chem       Date:  2012-06-14       Impact factor: 5.157

Review 3.  Novel therapeutic targets for pancreatic cancer.

Authors:  Shing-Chun Tang; Yang-Chao Chen
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 4.  Inhibition of Ras for cancer treatment: the search continues.

Authors:  Antonio T Baines; Dapeng Xu; Channing J Der
Journal:  Future Med Chem       Date:  2011-10       Impact factor: 3.808

5.  Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer.

Authors:  Victoria H Cruz; Emily N Arner; Wenting Du; Alberto E Bremauntz; Rolf A Brekken
Journal:  JCI Insight       Date:  2019-04-02

Review 6.  Selective Raf inhibition in cancer therapy.

Authors:  Vladimir Khazak; Igor Astsaturov; Ilya G Serebriiskii; Erica A Golemis
Journal:  Expert Opin Ther Targets       Date:  2007-12       Impact factor: 6.902

7.  Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth.

Authors:  Samuel C Falsetti; De-an Wang; Hairuo Peng; Dora Carrico; Adrienne D Cox; Channing J Der; Andrew D Hamilton; Saïd M Sebti
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

8.  Ras isoform abundance and signalling in human cancer cell lines.

Authors:  J Omerovic; D E Hammond; M J Clague; I A Prior
Journal:  Oncogene       Date:  2007-11-12       Impact factor: 9.867

9.  RalA-exocyst complex regulates integrin-dependent membrane raft exocytosis and growth signaling.

Authors:  Nagaraj Balasubramanian; Jeremy A Meier; David W Scott; Andrés Norambuena; Michael A White; Martin Alexander Schwartz
Journal:  Curr Biol       Date:  2009-12-10       Impact factor: 10.834

Review 10.  Pancreatic carcinogenesis.

Authors:  Jan-Bart M Koorstra; Steven R Hustinx; G Johan A Offerhaus; Anirban Maitra
Journal:  Pancreatology       Date:  2008-04-01       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.